Drug intelligence / Profile preview

FCN-911

Development stage: Preclinical
Lead developer: Fochon Biosciences
Modality: Small Molecules
Administration: Intravenous

Overview

FCN-911 is a small molecule pan-tropomyosin receptor kinase (TRK) inhibitor currently in preclinical development by Chongqing Fochon Pharmaceutical for the treatment of solid tumors. It is designed to inhibit the activity of the TRK family of kinases, which includes TRKA, TRKB, and TRKC (encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively). Chromosomal rearrangements resulting in NTRK gene fusions lead to the constitutive activation of these kinases, which act as oncogenic drivers in a wide variety of adult and pediatric solid tumors. By blocking these signaling pathways, FCN-911 aims to inhibit tumor cell growth and survival in patients with TRK-driven cancers.

Targets

NTRK1 (Tropomyosin-related receptor kinase A)NTRK2 (Tropomyosin-related kinase receptor type B)NTRK3 (Tropomyosin receptor kinase C)

Beyond the preview

Go deeper on FCN-911.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FCN-911.

Explore the full profile